Based on the greater than 90% homology in the kinase domains of LZK and DLK, here we tested the use of a DLK inhibitor as an inhibitor of LZK and this effective LZK inhibitor was then assessed for the ability to reduce HNSCC cell viability and suppress tumor growth in vivo. Here, MAP3K13 is linked to head and neck squamous cell carcinoma.